Regencell Bioscience (NASDAQ:RGC) Stock Price Up 6.7% – What’s Next?

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s stock price traded up 6.7% during trading on Wednesday . The stock traded as high as $5.86 and last traded at $5.8710. 58,345 shares traded hands during mid-day trading, a decline of 80% from the average daily volume of 296,605 shares. The stock had previously closed at $5.50.

Analyst Ratings Changes

A number of analysts have recently issued reports on RGC shares. Wall Street Zen cut shares of Regencell Bioscience from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Regencell Bioscience has an average rating of “Sell”.

Regencell Bioscience Stock Up 2.7%

The company has a 50 day moving average of $5.73 and a 200-day moving average of $18.33.

Institutional Investors Weigh In On Regencell Bioscience

A number of institutional investors have recently modified their holdings of the business. Seven Fleet Capital Management LP acquired a new position in shares of Regencell Bioscience in the fourth quarter valued at about $92,000. Amundi acquired a new stake in Regencell Bioscience in the 1st quarter worth about $219,000. Hudson Bay Capital Management LP acquired a new stake in Regencell Bioscience in the 4th quarter worth about $275,000. Bank of America Corp DE boosted its holdings in Regencell Bioscience by 59,113.8% in the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after purchasing an additional 17,143 shares during the period. Finally, XTX Topco Ltd bought a new stake in Regencell Bioscience in the 3rd quarter valued at about $598,000. Institutional investors own 0.13% of the company’s stock.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.